Helen Louise Evans
About Helen Louise Evans
Helen Louise Evans is a Principal Scientist at Bristol Myers Squibb with extensive experience in chemical biology and medicinal chemistry.
Current Position at Bristol Myers Squibb
Helen Louise Evans is currently serving as a Principal Scientist at Bristol Myers Squibb. In this role, she contributes her extensive background in chemical biology and medicinal chemistry to the development of novel therapeutics. Her expertise in the rational design and synthesis of small molecules, peptides, and protein-based chemical probes is instrumental in advancing the company's research and development initiatives.
Former Roles at Triplet Therapeutics and ImmunoGen
Before joining Bristol Myers Squibb, Helen Evans worked as a Senior Scientist, Conjugation Chemistry, at Triplet Therapeutics from 2019 to 2021. In this capacity, she focused on innovations in conjugation chemistry in Cambridge, Massachusetts. Prior to this role, she was Scientist I, Biochemistry, at ImmunoGen, Inc. from 2018 to 2019, where she applied her biochemical knowledge to various research projects.
Postdoctoral Research at Harvard University and MIT
Helen Evans held postdoctoral research positions at both Harvard University and the Massachusetts Institute of Technology (MIT). From 2014 to 2015, she was a Postdoctoral Associate at Harvard University. She continued her research at the Koch Institute for Integrative Cancer Research at MIT, where she served as a Postdoctoral Associate from 2015 to 2016, followed by a Postdoctoral Fellow from 2016 to 2018. During her time at MIT, Evans worked on developing chemical probes for cancer research.
PhD and Early Career at Imperial College London and GlaxoSmithKline
Helen Evans completed her PhD at Imperial College London, focusing on synthetic organic chemistry and radiochemistry within Hammersmith Hospital from 2010 to 2014. Her doctoral work enabled her to acquire a comprehensive understanding of these fields. Before her PhD, Evans gained industrial experience during her placement at GlaxoSmithKline from 2008 to 2009 in Stevenage, United Kingdom, which provided her with essential practical experience in a corporate setting.
Educational Background
Helen Evans holds an MChem degree in Chemistry from The University of Reading, where she studied from 2006 to 2010. Following this, she pursued a Doctor of Philosophy (PhD) at Imperial College London, specializing in synthetic organic chemistry and radiochemistry, earning her degree between 2010 and 2013. Her solid academic foundation laid the groundwork for her subsequent professional achievements and contributions to the field of chemical biology.